SCHEMBL24335121

SCHEMBL24335121

Cn1cc(-c2nc(C(C)(C)C)co2)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 11/20 0.38
NTRK1 P04629 2/20 0.38
RET P07949 2/20 0.38
EPHB2 P29323 2/20 0.38
KDR P35968 2/20 0.38
KDM5B Q9UGL1 1/20 0.36
CLK2 P49760 2/20 0.35
HIPK1 Q86Z02 2/20 0.35
DYRK2 Q92630 2/20 0.35
HIPK2 Q9H2X6 2/20 0.35
CLK4 Q9HAZ1 2/20 0.35
CLK1 P49759 1/20 0.35
DYRK1A Q13627 1/20 0.35
HIPK3 Q9H422 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
EPHX2 P34913 1/20 0.34
CCNC P24863 2/20 0.33
CDK8 P49336 2/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31595911 0.86 KCNT1 (0.37) ALOX5APCLK2HIPK1DYRK2HIPK2
SCHEMBL21069616 0.72 CCNC (0.45) DYRK1ACCNCCDK8
SCHEMBL28507167 0.71 ALDH1A1 (0.55) CCNCCDK8
SCHEMBL12403559 0.70 ALDH1A1 (0.46)
Hydrochloric Acid SCHEMBL17205026 0.70 ALDH1A1 (0.54) CCNCCDK8
SCHEMBL17806514 0.68 PIM1 (0.46) NTRK1RETEPHB2KDRCLK2
SCHEMBL18997028 0.68 CLK2 (0.40) NTRK1RETEPHB2KDRKDM5B
SCHEMBL19531827 0.68 KDM5A (0.42) NTRK1RETEPHB2KDRKDM5B
SCHEMBL15889313 0.67 LRRK2 (0.46) ALOX5APNTRK1RETKDRCLK1
SCHEMBL21070701 0.66 NLRP3 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS IRAK4, IRAK2, IRAK1 ALOX5AP 3540/4885NTRK1 457/4885RET 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.